Fewer early bacterial and viral infections following non-myeloablative vs. myeloablative conditioning for allotransplantation
نویسندگان
چکیده
منابع مشابه
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment option for both malignant and some benign hematological diseases. During the last decade, many of the newer high-dose regimens in different intensity have been developed specifically for patients with hematologic malignancies and solid tumors. Today there are three main approaches used prior to allogeneic tra...
متن کاملNon-myeloablative transplantation.
The concept of utilizing enhanced immunosuppression rather than myeloablative cytotoxic conditioning has allowed the engraftment of allogeneic stem cells from related and unrelated donors with lower early transplant-related mortality (TRM) and morbidity. This approach shifts tumor eradication to the graft-vs-host immune response directed against minor histocompatibility antigens expressed on tu...
متن کاملTargeting Myeloid Cells to the Brain Using Non-Myeloablative Conditioning
Bone marrow-derived cells (BMDCs) are able to colonize the central nervous system (CNS) at sites of damage. This ability makes BMDCs an ideal cellular vehicle for transferring therapeutic genes/molecules to the CNS. However, conditioning is required for bone marrow-derived myeloid cells to engraft in the brain, which so far has been achieved by total body irradiation (TBI) and by chemotherapy (...
متن کاملPemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning.
OBJECTIVES Successful treatment of severe, refractory Pemphigus vulgaris (PV) is reported. METHODS Reduced intensity, non-myeloablative conditioning was employed, followed by allogeneic hematopoietic stem cell transplantation (HSCT) from a fully matched sibling. RESULTS Treatment of refractory PV with myeloablation and subsequent allogenic HSCT has been previously reported, and sustained re...
متن کاملEarly myeloablative therapy for multiple myeloma.
The value of early myeloablative therapy supported by autologous bone marrow or blood progenitor cells was assessed in 72 patients with multiple myeloma who were treated within 1 year of initial therapy. Forty-five patients were consolidated during remission, and 27 patients were treated for primary refractory disease. Outcomes were compared with those of similar patients who did not receive in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2006
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2005.11.097